Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients

NCT03120832 is registered in ClinicalTrials.gov with Sensei Biotherapeutics, Inc. as lead sponsor.

NCT NCT03120832
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03120832 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1, Open Label Trial to Evaluate the Safety and Immunogenicity of PAN-301-1 in Cancer Patients
Lead sponsor
Sensei Biotherapeutics, Inc.
Phase
Phase 1
Overall status
Completed
Start date
December 31, 2016
Completion date
December 31, 2018
Enrollment
12 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer